Trial
NCT02269670
Phase II Study of Everolimus Beyond Progression
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Novartis
Condition
Estrogen Receptor-positive Breast Cancer
Intervention
everolimus
Why stopped
Slow to accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-05